Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized controlled study of dapagliflozin for reversal of left ventricular hypertrophy in type 2 diabetes mellitus
ChiCTR1900020955Phase 4Not yet recruiting
- Sponsor
- The Sixth Affiliated Hospital, South China University of Technology
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by The Sixth Affiliated Hospital, South China University of Technology. Primary endpoint: Left ventricular mass. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR1900020955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900020955.